HTG Completes HTP Product Next-Phase Development Milestone
Initially validated for neoplastic tissue, HTG has now validated HTP for use with normal FFPE tissue and other non-neoplastic tissues. In addition, the panel has been validated with PAXgene, a popular liquid blood-based sample type, and with extracted RNA from both fresh frozen and FFPE tissue samples.
In addition, to maximize sequencer flexibility, HTP is now validated across Illumina’s complete portfolio of production-scale sequencers including the NextSeq 500/550, NextSeq 1000/2000 and NovaSeq 6000 platforms. This will allow HTG’s customers to more efficiently sequence larger sample cohorts, which HTG believes will significantly increase the efficiency of data generation, in addition to reducing time to results and the overall cost of customer studies.
“We have been extremely pleased with the initial interest in the
Measuring approximately 20,000 mRNA targets using HTG’s proprietary HTG EdgeSeqTM technology, HTP can be deployed to profile a wide range of diseases, assist in identifying new drug candidates, develop molecular classification tools and discover critical biomarkers. HTG’s panel reduces sample amount requirements, is less sensitive to RNA degradation due to sample age, and provides faster turnaround times than other, currently available methods. HTP has also been shown to have a higher sample success rate than RNA-Seq for gene expression profiling. HTG previously released a series of White Papers highlighting these capabilities and performance measures which can be found here. HTG expects to continue to provide additional internal and expected third party validation data for HTP in future periods.
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expansion of the potential markets and applications for HTP, capabilities and benefits of HTP, additional commercial opportunities for HTP, demand for HP, and additional internal and third party validation for HTP. Words such as “designed to,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with the impact of the COVID-19 pandemic on us and our customers; the risk that HTP may not provide the benefits that we expect; risks associated with our ability to develop and commercialize our products, including HTP; the risk that HTP or our other products and services may not be adopted by biopharmaceutical companies or other customers as anticipated; our ability to manufacture our products to meet demand; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission (SEC), including under the “Risk Factors” heading of our Quarterly Report on Form 10-Q for the quarter ended
HTG Investor Contact:
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.